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Abstract. Thioridazine (TZ), an antipsychotic drug, renders
multidrug-resistant (MDR) cancer cells susceptible to cytotoxic
agents to which they were initially resistant, has anti-
prolilferative activity and apoptosis-inducing properties in
various tumor cell lines and cancer stem cells. Whereas the
anti-proliferative activity takes place at high concentrations that
ensure the intercalation of the compound between nucleic bases
(especially rich in G/C bases), much lower concentrations
inhibit the export function of the ABCB1 (P-glycoprotein),
which is responsible for the MDR phenotype of the cancer cell.
The co-administration of TZ with doxorubicin inhibits efflux of
doxorubicin and, hence, increases the intracellular
concentration of anticancer drug. The (+) and (–) enantiomers
of TZ have the same activities as TZ. The main focus of this
review is to present extensive evidence provided by our work,
confirmed by much later studies, as it supports adjuvant use of
TZ with an anticancer drug for MDR cancer therapy. 
Phenothiazines are heterocyclic compounds that have
specific and non-specific activities against constituents of the
plasma membrane of eukaryotes. Although the first
phenothiazines were synthesized in the late 19th century, the
basic phenothiazine structure is identical to that of the well-
known dye methylene blue, which was first prepared as a
stain in 1876 by the German chemist Heinrich Caro as a
derivative from an existing phenothiazine (1). Paul Ehrlich
studied methylene blue (Figure 1) for biological properties
and found that it could reduce the mobility of bacteria (1).
The demonstration by Bodoni at the end of the 19th century
that methylene blue could render a human lethargic, spurred
investigations of the possible use of this dye to control
psychosis (2). It took more than 50 years to produce a
colorless methylene blue-type compound by the French
chemist Charpentier of Rhone-Poulenc called
chlorpromazine (CPZ) that had the desired neuroleptic
properties for therapy psychosis (3). However, because of its
toxic side-effects, the compound was soon replaced with the
equally effective phenothiazine neuroleptic thioridazine (TZ)
whose most frequent side-effect was somnolence (Figure 1).
The early wide use of CPZ indicated that, apart from their
basic neuroleptic action related to the blockade of
dopaminergic receptors, CPZ affected diverse biological
activities, such as the calcium transporter calmodulin, protein
kinase C, as well as many other enzymes that, when
inhibited by CPZ, promoted anti-proliferative effects (4, 5).
The enhancement of antibiotic activity by CPZ on bacteria
and the demonstration that multidrug-resistant (MDR)
Mycobacterium tuberculosis could be inhibited in its
replication by CPZ and TZ (6) as well as the reversal of
antibiotic resistance was the result of inhibition of the efflux
pump system of mycobacteria (6) and bacteria (7). In
addition, similar inhibitory effects of the ABCB1 transport
function were demonstrated using MDR mouse T-lymphoma
cells (8). The relevant possibilities to MDR cancer were
supported by the anti-helmintic and antibacterial activities of
phenothiazines described in the 1930s and 1940s (5).
Phenothiazines have been in use for the treatment of
psychiatric disorders since the 1950s. In addition, various
other effects of phenothiazines have since been described,
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such as anti-mycobacterial (9), anti-plasmid (10) and
immunomodulatory (11) activities. The substituents in the
phenothiazine ring, which increase lipophilicity, amplify
their anti-proliferative activity in cancer cells (12). The
presence of different substituents into the phenothiazine
skeleton, as well as the modification of the tricyclic ring
system, alters their biological effect (13). Because of their
highlighted biological activity, numerous derivatives of
phenothiazines have been synthesized and patented (5). 
Thioridazine, (10-[2-(1-methyl-2-piperidinyl)ethyl]-2-
(methylthio)-10H-phenothiazine), was previously used
extensively as an antipsychotic drug; however, there is an
increasing number of studies demonstrating its anticancer,
multidrug resistance-reversing and apoptosis-inducing
properties in various tumor cell lines. This review intends to
give an overview of the MDR-reversing activity of
thioridazine that has resulted from our decades of published
research studies, many of which have been recently
confirmed by others, although correct citation of their
existence has been omitted willfully or otherwise.
Membrane Destabilizing Effects
Phenothiazines demonstrate a strong affinity to lipid bilayers
of cell membranes because of the high degree of lipophilicity
of the phenothiazine ring (12). Thioridazine (TZ) interacts with
the inner mitochondrial membrane. Consequently, TZ presents
with antioxidant and peroxidation activities on membrane
lipids of the mitochondria, with these effects resulting in
transient alterations of mitochondrial permeability, thus
promoting release of cytochrome c from mitochondria (14).
Effect on Cell Cycle
According to in silico gene signature based studies, TZ inhibits
the phosphatidylinositol-3’-kinase (PI3K)/Akt pathway and,
thus, exerts cytotoxicity in ovarian cancer cells (15).
Translationally controlled tumor protein (TCTP) is an
essential regulator of apoptosis and cell cycle events (16). In
508 breast cancers, high-TCTP status is associated with
aggressive G3-grade tumors, predicting poor prognosis. TZ
increases P53 expression by counteracting the ubiquitination
of P53 that is enhanced by TCTP (17).
Anti-calmodulin Activity
Calmodulin is a calcium binding protein that regulates
calcium-dependent biochemical processes and, hence is
involved in a large variety of cellular functions. Since TZ is
a potent inhibitor of calmodulin, calcium binding and many
calcium-dependent enzymes that are involved in cellular
proliferation become destabilized. Thus, when calmodulin is
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Figure 1. Chemical structure of some important phenothiazines. 
inhibited from binding calcium by TZ, these enzymes deny
access to calcium, and, hence, their reduced activity results
in the inhibition of cell proliferation (12). Similarly, many
biochemical pathways, dependent upon access to calcium,
are similarly inhibited (12, 18).
Effect on DNA Damage
TZ can interfere with DNA damage responses and DNA
repair. Furthermore, TZ is an inhibitor of Tousled-like
kinases (TLKs), enzymes responsible for the maintenance of
genomic stability (19). As described previously, TZ has anti-
plasmid activity by eliminating the drug resistance-carrying
plasmids of bacteria (20).
TZ as Dopamine Receptor Antagonist
TZ is an antagonist of the dopamine D2 receptor (DRD2)
and, according to previous reports, DRD2 could be a
promising therapeutic target in cervical cancer therapy. It has
been shown that TZ inhibits cellular proliferation through
down-regulation of DRD2 expression. Moreover, TZ can
inhibit proliferation of human uterine cervical carcinoma
cells and induce apoptosis and necrosis (21). TZ can inhibit
the PI3K/Akt/mTOR/p70S6K signaling pathway and has
cytotoxic activity on cervical and endometrial cancer cells
by inducing cell cycle arrest and apoptosis (22). 
Activity on Stem Cells
TZ is a selective inducer of the differentiation of cancer stem
cells (CSC) and the anti-CSC activity of TZ is due to its
antagonistic effect on DRD2 receptors that are differentially
expressed on neoplastic stem cells. It is important to note
that TZ has no effect on normal human somatic stem cells
implying that TZ could be a selective anti-CSC drug (23).
TZ exerts an apoptotic effect in brain-derived tumors;
furthermore, the sensitivity of neoplasm tissue to thioridazine
is higher than that on primary (normal) brain cells (24). With
the use of bioinformatic tools, it has been demonstrated that
TZ is a potent anti-glioblastoma and anti-glioblastoma cancer
stem-like cell agent. Moreover, because autophagy might be
a major mechanism of the anti-glioblastoma activity and TZ
has proved to be an effective glioblastoma tumor growth
inhibitor that can induce autophagy in vivo, the rediscovery
of TZ as an anticancer agent could be used as a powerful
strategy against malignant tumors with a poor prognosis (25).
Apoptosis Induction
TZ induces apoptosis in leukemic cells without any influence
on the viability of normal lymphocytes (26). It also induces
apoptosis of B16 melanoma cells and demonstrates in vivo
anti-tumor activity (27). The in vivo activity of TZ was
studied using female C57/Bl mice. Animals were inoculated
with wild-type B16 melanoma cells by intravenous (i.v.)
injection into the tail vein. Mice were treated with TZ (10 and
15 mg/kg × 3/weeks intraperitoneally (i.p.) or 15 and 25
mg/kg/day per os (p.o.)) and, after autopsy, the lung weight
and number of pulmonary melanoma colonies were
determined. TZ administration (i.p. or p.o.) resulted in the
reduction of lung tumor burden and an increase in mice
survival (27).
It was demonstrated that TZ induces apoptosis of the
MDR mouse T-lymphoma cells at 5 and 10 μg/ml
concentrations (8). During apoptosis, the plasma membrane
undergoes multiple changes: the translocation of
phosphatidylserine from the inner to the outer leaflet of the
plasma membrane can be detected by annexin V. After
treatment with 10 μg/ml of TZ, 49.54% of the cells were
early-apoptotic and 27.26% showed late-apoptotic and
necrotic features, although the proportion of dead cells was
3.4% in MDR mouse T-lymphoma cells (8). The apoptosis-
inducing effect of TZ was confirmed by other studies using
various cell lines (28).
Efflux Pump Inhibition
The major mechanism for the MDR phenotype is the
overexpression of ATP-dependent transporters known as the
ATP-binding cassette (ABC) family. In humans, the three
major types of MDR proteins include members of the ABCB
(ABCB1/MDR1/P-glycoprotein), the ABCC (ABCC1/MRP1,
ABCC2/MRP2, probably also ABCC3–6 and ABCC10–11)
and the ABCG (ABCG2/MXR/BCRP) sub-family (29). The
relationship between ABC expression levels and sensitivity
to drugs or possible drug candidates is of great importance
concerning anticancer chemotherapy.
Substances, such as verapamil and TZ, which can block
ABCB1 or P-glycoprotein, can reverse resistance of
doxorubicin-resistant sarcoma 180 (S180) cells completely
(30). According to Spengler et al., TZ induces apoptosis of
the MDR lymphoma cells and inhibits the activity of their
overexpressed ABCB1 transporter. However, the
concentrations that produce these in vitro results are
extremely high and greater than that clinically employed for
the therapy of severe psychosis (8). 
Anti-angiogenesis
Angiogenesis is essential for tumor growth and metastasis
and targeting angiogenesis could be a promising objective
for anticancer drug development. Expression of vascular
endothelial growth factor (VEGF) and hypoxia-inducible
factor 1α (HIF-1α), as well as the phosphorylation of
VEGFR-2 were reduced in a thioridazine-treated tumor (31).
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TZ is an angiostatic agent found to effectively inhibit
angiogenesis in a murine tumor model reducing microvessel
density in vivo (32).
Stereochemistry and Pharmacological Activity
The consideration of stereochemistry in drug action is gaining
ever-greater attention in medical practice. Many of the drugs
currently used in psychiatric practice are mixtures of
enantiomers. For some therapeutics, single-enantiomer
formulations can provide greater selectivity for their biological
targets and/or better pharmacokinetics compared to the
mixture of enantiomers. When both a single enantiomer and a
racemic formulation of a drug are available, the information
from experimental evidences should be used to decide which
formulation is most appropriate (33). The potential advantages
of using single enantiomers of a chiral drug were investigated
by Csonka et al. (34). The equilibrium between the (+) and 
(–) isomers influences the binding affinities of the enantiomers
to different ligands or receptors. “Do the racemate TZ and its
enantiomers express different activities against cancer cell
lines?” This question was based upon observations published
by others who suggested that “the (–)-TZ enantiomer had
slightly more catalepsy (neuroleptic)” (35). Nevertheless, a
variety of pharmacological studies, as reported by Svendsen
et al. (35), indicate significantly greater binding of the (–)-TZ
enantiomer to the D1 receptor of the rodent brain. Regardless,
our results clearly demonstrate that the racemate TZ and its
enantiomers have essentially the same activity against cancer
cell lines with respect to the inhibition of replication, induction
of apoptosis and inhibition of ABCB1 (34). The central
nervous system (CNS) receptor stereospecificity of (+) and 
(–)-TZ was first described by Svendsen et al. in 1988 (35).
Optical isomers, such as those of TZ, exhibit significant
differences in their affinities for receptor sites,
biotransformation and binding to serum and tissue proteins.
Separation of the racemate TZ into its enantiomers in the
human body has been measured (36). In these investigations,
the (–) enantiomer was found to be at higher concentrations
than the (+) enantiomer in the different tissues. The general
possibility for using the resolution of commercially available
racemates in therapeutics for an anxiolytic effect has been
described by Baumann et al. (36) based on the investigations
and statements made by Ariens et al. (37). The role of the
chirality of other compounds known to affect ABCB1, such as
the enantiomers of verapamil, has been investigated. These
latter studies indicated that the L and the D forms of verapamil
had equal abilities to reverse the in vitro resistance of MDR
leukemic cells to drugs, such as vincristine (38). The
mechanism of action of TZ has been analyzed in detail by
Spengler et al. who showed that the racemate is able to induce
the apoptosis of MDR mouse T-lymphoma cells (8). In this
latter study, the differential effects of the two TZ enantiomers
were not examined. As previously stated, the anti-proliferative
effects of the racemate and (+) and (–) enantiomers of TZ on
MDR mouse T-lymphoma cells overexpressing ABCB1 were
investigated by Csonka et al. (34) and no significant
differences were found between the three compounds.
In order to avoid the toxic side-effect of resistance-reversing
compounds, drugs with selective inhibition of the MDR in
cancer cells are needed. To achieve this effect, three classes of
known neuroleptic drugs (methotrimeprazine, clopenthixol and
butaclamol isomers) with active and inactive stereoisomers
were tested for MDR efflux pump inhibition on mouse T-
lymphoma cell lines (39). Their anti-proliferative effects on
sensitive and MDR cancer cell cultures were compared with
those of the classical resistance modifier verapamil. It was
confirmed that enantiomers of phenylalkylamines proved to be
equally potent inhibitors of drug transport by ABCB1 (39).
However, CNS-active and -inactive butaclamol enantiomers
exerted slightly different effects on the reversal of the MDR
phenotype, which means that drug binding might have weak
enantioselectivity for ABCB1 (39), suggesting that some
enantiomers of compounds that inhibit ABCB1 can be
exploited as adjuvants to cytostatic chemotherapy of cancer in
order to increase the efficacy of the anticancer agent. However,
the separate use of one enantiomer of TZ versus the other did
not appear to provide any advantage over racemic TZ for the
adjuvant therapy of MDR cancer.
Role of TZ in Combined Chemotherapy
The combination therapy using a conventional
chemotherapeutic drug with an agent that can improve the
action of the anticancer drug without any additional side-
effects could be a good approach to treat MDR cancer. TZ
showed a moderate synergism to doxorubicin in P388/ADR
murine leukemia cells described by Ramu et al. (40).
It has been confirmed that calmodulin inhibitors
significantly enhanced the cytotoxic effects of doxorubicin
in the resistant but not parent-sensitive P388 cells (41). To
administer TZ and doxorubicin to in vitro and in vivo
systems, polymeric micelles have been designed as delivery
carriers (42). The combination therapy with TZ-free or TZ-
loaded micelles was effective in decreasing the population
of cancer stem cells. However, TZ-loaded micelles had lower
antitumor efficacy than doxorubicin-loaded micelles; the
combination therapy of TZ-loaded and doxorubicin-loaded
micelles presented a greater antitumor effect than
doxorubicin-loaded micelles alone (42).
Conclusion
The first demonstrations that phenothiazines could inhibit
cancer growth were reported during the early 1950s. Since
those early years, many studies have been published
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describing that phenothiazines can inhibit the growth of
some types of cancers (43). Based on the biological activity
of TZ, such as interference with membrane function, DNA
repair, signaling pathways, cell cycle, apoptosis induction,
efflux inhibition and, also, its synergistic effect with
doxorubicin, renders TZ a powerful anticancer drug and
adjuvant in combined chemotherapy.
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